847260-47-3Relevant academic research and scientific papers
BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE
-
Page/Page column 31, (2019/01/16)
Compounds, pharmaceutical compositions containing the same useful in the treatment of Alzheimer's disease are disclosed. Methods of preparing the compounds and compositions and use thereof are also disclosed.
AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE
-
Page/Page column 42; 43, (2019/09/18)
The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC50 values and permeability ac
Metal-free arylation of pyrimidines through a photochemical process
Ruch, Jonas,Aubin, Ariane,Erbland, Guillaume,Fortunato, Audrey,Goddard, Jean-Philippe
supporting information, p. 2326 - 2329 (2016/02/18)
Pyrimidinyl and pyrazinyl radicals were generated under moderate energetic irradiation conditions (UVA), and proved to be prompt to undergo C-C bond formation processes. Hetero-biaryl derivatives were obtained in good to high yields with highly interesting functional group selectivities. Bis hetero-biaryls were also easily accessible leading to original compounds, ready for further transformations. Experiments supporting radical processes have been reported.
QUINOXALINE DERIVATIVES AND ORGANIC LIGHT-EMITTING DIODES COMPRISING THE SAME
-
Page/Page column 10, (2012/12/14)
A quinoxaline derivative represented by Formula (I) of or Formula (II) of is provided. In Formula (I) or (II), R1, R2, R3 and R4 are, independently, hydrogen, halogen, methyl, ethyl, propyl, butyl, aryl or heteroaryl, for example phenyl, furyl, thienyl, pyridyl, pyrimidyl, benzothiazolyl or benzoimidazolyl. The disclosure also provides an organic light-emitting diode including the quinoxaline derivative.
ELECTRONIC DEVICE INCLUDING A PYRIMIDINE COMPOUND
-
Page/Page column 49, (2012/07/13)
There is provided a compound having Formula I or Formula II In Formula I: R1-R4 are the same or different and are H, D, alkyl, silyl, alkoxy, cyano or aryl. At least two of R1-R4 are aryl groups and at least one aryl group includes an N,O,S-heterocycle. When two of R1-R4 include N-carbazolyl groups, two of R1-R4 are not aryl; In Formula II: Q is a single bond or a hydrocarbon aryl; and R5 and R6 are the same or different at each occurrence and are H, D, alkyl, silyl, alkoxy, cyano or aryl. At least one of R5 and at least one of R6 are an aryl group. At least one aryl group includes an N,O,S-heterocycle.
NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME
-
Page/Page column 45, (2010/11/08)
A compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, which is useful for a prophylactic and/or therapeutic treatment of a microbial infectious disease. [R1 is hydrogen atom, or a linear C1-6 alkylcarbonyl group; R2 is hydrogen atom, or a C1-6 alkylcarbonyl group; R3 is hydrogen atom, a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C1-6 alkenyl group, a C2-6 alkenylcarbonyl group, a C2-6 alkynyl group, or an Ar-B- group (Ar represents an aryl group, or a heterocyclic group, and B is a C1-6 alkyl group, a C1-6 alkylcarbonyl group, a C2-6 alkenyl group, a C2-6 alkenylcarbonyl group, or a C2-6 alkynyl group); R5, R6, R7, and R8 represent hydrogen atom, a C1-6 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, or an Ar-B'- group (B' is a C1-6 alkyl group, a C2-6 alkenyl group, or a C2-6 alkynyl group); X is oxygen atom, or an -NR4- group (R4 is hydrogen atom, a C1-6 alkyl group, or a C1-6 alkyl group which may be substituted with an Ar group); and R4' is hydrogen atom, or a group represented by the aforementioned formula (a) (R3" and R4" represent hydrogen atom, or a linear or branched C1-6 alkylcarbonyl group)]
